Get started
Author

Liyang Diao

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
2020 · Matthew R. Henn, Edward J. O’Brien, et al. · Gastroenterology · 126
PDF
Changes in vaginal community state types reflect major shifts in the microbiome
2017 · J. Paul Brooks, Gregory A. Buck, et al. · Microbial Ecology in Health and Disease · 110
Local Ancestry Corrects for Population Structure in Saccharomyces cerevisiae Genome-Wide Association Studies
2012 · Liyang Diao, Kevin C Chen · Genetics · 30
PDF
Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency
2025 · Alexander Solovyov, Julie M. Behr, et al. · Nature Communications · 28
Sporulation Genes Associated with Sporulation Efficiency in Natural Isolates of Yeast
2013 · Parul Tomar, Aatish Bhatia, et al. · PLoS ONE · 24
PDF
MixMir: microRNA motif discovery from gene expression data using mixed linear models
2014 · Liyang Diao, Antoine Marcais, et al. · Nucleic Acids Research · 20
PDF
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With RecurrentClostridioides difficileInfection
2023 · Timothy J Straub, Mary-Jane Lombardo, et al. · Clinical Infectious Diseases · 18
PDF
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
2026 · Jessica A. Bryant, Marin Vulić, et al. · Nature Medicine · 13
Multiple roles of PIWIL1 in mouse neocorticogenesis
2017 · Barbara Viljetic, Liyang Diao, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 9
PDF
Tu2019 - Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild to Moderate Ulcerative Colitis (UC)
2018 · Sheri Simmons, Liyang Diao, et al. · Gastroenterology · 5
Abstract 742: PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models
2024 · Nicolas Severe, Amanda Facklam, et al. · Cancer Research · 4
85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis
2018 · Misra Bharat, John Curran, et al. · Gastroenterology · 4
Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
2017 · Matthew Henn, Christopher Ford, et al. · Open Forum Infectious Diseases · 4
PDF
The shuffle index and evaluation of models of signal transduction pathways
2007 · Edward E. Allen, Liyang Diao, et al. · ACM Southeast Regional Conference (ACMSE) · 4
LINE-1 ORF1p is a shared and immunogenic antigen in cancer
2025 · Wilson McKerrow, Megan Snyder, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Abstract 2908: EDB+FN is an attractive therapeutic target in oncology: Insights from protein expression analysis of solid tumors
2024 · Sara Lewandowski, Liyang Diao, et al. · Cancer Research · 3
623 – Ser-287, an Investigational Microbiome Therapeutic, Induces Widespread Transcriptional Changes Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild-To-Moderate Ulcerative Colitis
2019 · Liyang Diao, Mauris C. Nnamani, et al. · Gastroenterology · 3
PDF
1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
2018 · Christopher Ford, Matthew Henn, et al. · Open Forum Infectious Diseases · 3
Author Correction: Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency
2025 · Alexander Solovyov, Julie M. Behr, et al. · Nature Communications · 2
LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics
2021 · Timothy J Straub, Liyang Diao, et al. · Open Forum Infectious Diseases · 2
809 Rapid Conversion of Primary to Secondary Bile Acids in Subjects With Recurrent Clostridioides Difficile Infection (cdi) Following Ser-109, an Investigational Microbiome Therapeutic
2021 · Jessica A. Bryant, Liyang Diao, et al. · Gastroenterology · 2
681 Ser-301, an Investigational, Rationally-designed Bacterial Consortium for Mild-to-moderate Ulcerative Colitis, Recapitulates the Effects of Ser-287, a Consortium of Firmicute Spores, on Remission Associated Microbial Metabolites and Host Gene Expression
2021 · Asuncion Martinez, Edward J. O'Brien, et al. · Gastroenterology · 2
621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
2018 · Matthew Henn, Christopher Ford, et al. · Open Forum Infectious Diseases · 2
PDF
Identification of novel regulators of LINE-1 expression via CRISPR/Cas9 screening
2025 · Ozgur Oksuz, Chong Chu, et al. · Mobile DNA · 1
Abstract 1373: Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication
2024 · Krystal Watkins, Liyang Diao, et al. · Cancer Research · 1
Works count: 38
Citation count: 421
H-index: 9
I10-index: 8
Year
Topic
Type